Cargando…

Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model

Colorectal cancer is a poorly immunogenic. Such property can be reverted by using ICD. However, ICD inducers can also induce the expression of inhibitory checkpoint receptors CD47 and PD-L1 on tumor cells, making CRC tumors resistant to mainly CD8 T cell killing and macrophage-mediated phagocytosis....

Descripción completa

Detalles Bibliográficos
Autores principales:	Alimohammadi, Reza, Mahmoodi Chalbatani, Ghanbar, Alimohammadi, Masoumeh, Ghaffari-Nazari, Haniyeh, Rahimi, Arezou, Mortaz, Esmail, Mossafa, Nariman, Boon, Louis, Jalali, Seyed Amir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922272/ https://www.ncbi.nlm.nih.gov/pubmed/36774400 http://dx.doi.org/10.1038/s41598-023-29363-9

Ejemplares similares

Combining ablative radiotherapy and anti CD47 monoclonal antibody improves infiltration of immune cells in tumor microenvironments
por: Rostami, Elham, et al.
Publicado: (2022)

Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy
por: Alimohammadi, Reza, et al.
Publicado: (2020)

The Nuclear Factor Kappa B (NF-kB) signaling in cancer development and immune diseases
por: Zinatizadeh, Mohammad Reza, et al.
Publicado: (2020)

CAR-T cells: Early successes in blood cancer and challenges in solid tumors
por: Dana, Hassan, et al.
Publicado: (2021)

Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer
por: Park, Dawon, et al.
Publicado: (2018)

Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) as secondline therapy for patients with advanced urothelial cancer
por: Zhang, Sheng, et al.
Publicado: (2016)

Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy: A case report
por: Wang, Danping, et al.
Publicado: (2019)

Harnessing Macrophages through the Blockage of CD47: Implications for Acute Myeloid Leukemia
por: Melo Garcia, Luciana, et al.
Publicado: (2021)

Association of the genetic polymorphisms in inhibiting and activating molecules of immune system with rheumatoid arthritis: A systematic review and meta-analysis
por: Mousavi, Mohammad Javad, et al.
Publicado: (2021)

A New World of Biomarkers and Therapeutics for Female Reproductive System and Breast Cancers: Circular RNAs
por: Tran, Anh M., et al.
Publicado: (2020)

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
por: Bai, Liangliang, et al.
Publicado: (2019)

Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead
por: Soltantoyeh, Tahereh, et al.
Publicado: (2021)

Determination of the psychometric properties of the Patients’ Self-Efficacy Scale in blood pressure patients
por: Ghadiri, Raheleh, et al.
Publicado: (2018)

Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4)
por: Chen, Chin-Fan, et al.
Publicado: (2008)

Interstitial lung disease in a patient treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) for metastatic colorectal cancer
por: Hannan, Liam M, et al.
Publicado: (2012)

In silico Analysis, Molecular Docking, Molecular Dynamic, Cloning, Expression and Purification of Chimeric Protein in Colorectal Cancer Treatment
por: Dana, Hassan, et al.
Publicado: (2020)

The Hippo Tumor Suppressor Pathway (YAP/TAZ/TEAD/MST/LATS) and EGFR-RAS-RAF-MEK in cancer metastasis
por: Zinatizadeh, Mohammad Reza, et al.
Publicado: (2019)

Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian Cancer
por: Lee, Hee Jun, et al.
Publicado: (2013)

The Role and Function of Ras-association domain family in Cancer: A Review
por: Zinatizadeh, Mohammad Reza, et al.
Publicado: (2019)

Integrative and in-vitro analysis reveal hsa_circ_001787 can act as a diagnostic biomarker for colorectal cancer
por: Chalbatani, Ghanbar Mahmoodi, et al.
Publicado: (2021)

Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice
por: Ghaffari-Nazari, Haniyeh, et al.
Publicado: (2015)

Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells
por: Lian, Shu, et al.
Publicado: (2019)

Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach
por: Mahmoodi Chalbatani, Ghanbar, et al.
Publicado: (2019)

Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients
por: Nagashima, Makoto, et al.
Publicado: (2014)

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer
por: Gravalos, Cristina, et al.
Publicado: (2012)

Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study
por: Le Roy, Bertrand, et al.
Publicado: (2016)

Evaluation of the Frequency and Anatomy of Radix Entomolaris and Paramolaris in Lower Molars by Cone Beam Computed Tomography (CBCT) in Northern Iran, 2020-2021: A Retrospective Study
por: Rokni, Hadiseh A, et al.
Publicado: (2023)

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
por: Qin, Shukui, et al.
Publicado: (2018)

Carbonic Anhydrase IX: A Renewed Target for Cancer Immunotherapy
por: de Campos, Najla Santos Pacheco, et al.
Publicado: (2022)

All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controlled trial
por: Shi, Jie, et al.
Publicado: (2019)

The integrative multi-omics approach identifies the novel competing endogenous RNA (ceRNA) network in colorectal cancer
por: Mahmoodi Chalbatani, Ghanbar, et al.
Publicado: (2023)

Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study
por: Emmanouilides, Christos, et al.
Publicado: (2007)

Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study
por: Tezuka, Tohru, et al.
Publicado: (2013)

Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin—folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial
por: Messager, Mathieu, et al.
Publicado: (2016)

Cardiac metastasis from colon cancer effectively treated with 5-fluorouracil, leucovorin, and oxaliplatin (modified FOLFOX6) plus panitumumab: a case report
por: Tsujii, Yoshiki, et al.
Publicado: (2017)

A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma
por: Horimatsu, Takahiro, et al.
Publicado: (2017)

A template-free approach for waveform extraction of gravitational wave events
por: Akhshi, A., et al.
Publicado: (2021)

Assessment of bioaerosol particle characteristics at different hospital wards and operating theaters: A case study in Tehran
por: Bolookat, Fatemeh, et al.
Publicado: (2018)

1′,5-Dinitro-2′-phenyl-2′,3′,5′,6′,7′,7a’-hexahydrospiro[indoline-3,3′-1′H-pyrrolizin]-2-one
por: Sarrafi, Yaghoub, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_cubn11v56kln1ucfegourq3nml